High-dose chemotherapy in germ-cell tumors

Annals of Oncology

Volumn 7, Issue 10, 1996, Pages 997-1003

  Droz, J P ^a   Culine, S ^b   Biron, P ^a   Kramar, A ^c  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

developmental therapeutics; germ cell tumors; high dose chemotherapy; paclitaxel; prognostic factors

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIMETHOATE; ETOPOSIDE; PACLITAXEL;

CLINICAL TRIAL; GERM CELL TUMOR; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0030461454     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010523     Document Type: Review

References (65)

1. Einhorn LH. Testicular cancer: A new and improved model. J Clin Oncol 1990; 8: 1777-81.
2. Droz JP, Kramar A, Rey A. Prognostic factors in metastatic disease. Semin Oncol 1992; 19: 181-9.
3. Farhat F, Culine S, Théodore C et al. Cisplatin and ifosfamide with either vinblastine or etoposidc as salvage therapy for refractory or relapsing germ cell tumors patients: The Institut Gustave Roussy experience. Cancer 1996; 77: 1193-7.
4. Culine S, Kramar A, Biron P, Droz JP. Chemotherapy in adult germ cell tumors. Crit Rev Oncol/Hematol 1996; 22: 229-63.
5. Highby DJ, Wallace HJ, Albert D, Holland JF. Diamminodichloroplatinum in the chemotherapy of teslicular tumors. J Urol 1974; 112: 100-4.
6. Samuels ML, Johnson DE, Holoye PY. Continuous intravenous blcomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep 1975; 59: 563-70.
7. Williams SD. Einhorn LH, Greco FA et al. VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer 1980; 46: 2154-8.
8. Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH. Ifosfamide in refractory male germ cell tumors. J Clin Oncol 1986; 4: 28-34.
9. Einhorn LH, Donohuc JP. Cis-diamminodichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-8.
10. Samson MK, Rivkin SE, Jones SE et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southern Oncology Group Study. Cancer 1984; 53: 1029-35.
11. Nichols CR, Williams S, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9: 1163-72.
12. Buckner CD, Clift RA, Fefer A et al. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic teslicular neoplasm. Cancer Chemother Rep 1974; 58: 709-14.
13. Poslmus PE, Mulder MH, Sleijfer DT et al. High-dose etoposide for refractory malignancies: A phase I study. Cancer Treat Rep 1984; 68: 1471-4.
14. Blijham G, Spitzer G, Litam J et al. The treatment of advanced testicular carcinoma with high-dose chemotherapy and autologous marrow support. Eur J Cancer 1981; 17:433-41.
15. Droz JP, Pico JL, Ghosn M et al. Long-term survivors after salvage high-dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer 1991; 27:831-5.
16. O'Reilly SM, Rustin GJS, Smith DB, Newlands ES. Single agent activity of carboplatin in patients with previously untreated non seminomatous germ cell tumours. Ann Oncol 1992; 3: 163-4.
17. Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer. A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-9.
18. Ibrahim A, Zambon E, Bourhis JH et al. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur J Cancer 1993; 29A: 1398-403.
19. Motzer RJ, Gulati SC, Tong WP et al. Phase 1 trial with pharmacokinetic analyses of high-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 1993; 53: 3730-5.
20. Lotz JP, Machover D, Malassagne B et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 1991; 9: 1860-70.
21. Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. J Clin Oncol 1994; 12: 1223-31.
22. Mandanas RA, Broun ER, Nichols CR et al. Phase I/II dose escalation study of carboplatin (CBDCA) and etoposide (VP-16) with autologous marrow support done in tandem for refractory germ cell tumors. Proc Am Assoc Cancer Res 1993; 12: 240 (Abstr).
23. Motzer RJ, Mazumdar M, Bosl GJ et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996; 14: 1098-105.
24. Broun ER, Nichols CR, Tricot G et al. High-dose carboplatin/ VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant 1991; 7: 53-6.
25. Fields KK, Elfenbein GJ, Lazarus HM et al. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 1995; 13: 323-32.
26. Broun ER, Gonin R, Nichols CR, Einhorn LH. Retrospective analysis of carboplatin area under the curve (AUC) in relation to toxicity and survival in testis cancer patients undergoing high-dose therapy with autologous bone marrow transplantation. Proc Am Soc Clin Oncol 1996; 15: 267.
27. Rodenhuis S, Vlasveld LT, Dubrelman R et al. Feasability study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer. Ann Oncol 1992; 3: 463-7.
28. Rodenhuis S, Van der Wall E, Schornagel JH et al. Development of a multiple high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa and carboplatin with peripheral stem-cell transplantation. Proc Am Soc Clin Oncol 1994; 13: 248.
29. Droz JP, Pico JL, Kramar A. Role of autologous bone marrow transplantation in germ-cell cancer. Urol Clin North Am 1993; 20: 161-71.
30. Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ cell tumors: Recent advances and future directions. J Natl Cancer Inst 1992; 84: 1703-9.
31. Droz JP, Kramar A, Pico JL. Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours. Eur J Cancer 1993; 29A: 818-21.
32. Linkesch W, Greinix HT, Hocker P et al. Long term follow up of phase I/II trial ultra-high carboplatin, VP-16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc Am Soc Clin Oncol 1993; 12: 232.
33. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-45.
34. Broun ER, Nichols CR, Einhorn LH, Tricot GJK. Salvage therapy with high-dose chemotherapy and autologous bonemarrow support in the treatment of primary non-seminomatous mediastinal germ-cell tumors. Cancer 1991; 68: 1513-5.
35. Pico JL, Ostronoff M, Droz JP et al. High-dose chemotherapy with cisplatin, etoposide and cyclophosphamide (PEC protocol) followed by autologous bone marrow support in nonseminomatous germ cell tumors. Proc Am Soc Clin Oncol 1989; 8: 12.
36. Biron P, Brunat-Mentigny M, Bayle JY et al. Cisplatinum-VP 16 and ifosfamide (VIC) + autologous bone marrow transplantation in poor prognostic non-seminomatous germ cell tumors. Proc Am Soc Clin Oncol 1989; 8: 148.
37. Einhorn LH, Weathers T, Loehrer P, Nichols CR. Long-term follow-up of second line chemotherapy with vinblastine, ifosfamide and cisplatin in disseminated germ cell tumors. Proc Am Soc Clin Oncol 1996; 15: 240.
38. Droz JP, Kramar A, Nichols C et al. Second-line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in reccurent germ cell cancer: Assignement of prognostic groups. Proc Am Soc Clin Oncol 1993; 12: 229.
39. Debono D, Warren G, Schach B et al. Dose-intensive carboplatin and etoposide (VP-16) with autologous bone marrow transplantation in refractory germ-cell tumors. Proc Am Soc Clin Oncol 1994; 13:240 (Abstr).
40. Bokemeyer C, Harstrick A, Ruther U et al. Sequential treatment with high-dose VIP-chemotherapy plus peripheral blood stem cell support in advanced germ cell cancer. Proc Am Soc Clin Oncol 1995; 14: 230.
41. Bokemeyer C, Schmoll HJ. Treatment of advanced germ cell tumours by doses intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). Eur Urol 1993; 23: 223-30.
42. Culine S, Droz JP, Delva R et al. Rapidely recycled intensive alternating chemotherapy in heavily pretreated progressive non-seminomatous germ cell tumors. A feasibility study. Urol Oncol 1995; 1: 109-14.
43. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-83.
44. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin refractory testicular cancer. Ann Oncol 1996; 7: 31-4.
45. Christou A, Roth B, Fox S et al. Phase II trial of paclitaxel in refractory germ cell neoplasms. Proc Am Soc Clin Oncol 1996; 15: 249.
46. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: Rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
47. Motzer RJ, Bosl GJ, Tauer K, Golbey R. Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Cancer Treat Rep 1987; 71: 197-8.
48. Schmoll HJ. The role of ifosfamide in testicular cancer. Contr Oncol 1987; 26: 234-55.
49. Hartlapp JH, Weissbach L, Horstmann-Dubral B. Ifosfamide monotherapy in testicular cancer. Contr Oncol 1987; 26: 256-61.
50. Einhorn LH, Williams SD. Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer 1980; 46: 1339-44.
51. Lecesne A, Droz JP, Azab M et al. Phase II trial with single agent epirubicin as salvage chemotherapy in refractory germ cell tumors. Proc Am Soc Clin Oncol 1990; 9: 145.
52. Lecesne A, Droz JP, Kattan J et al. Phase II trial of a combination of ifosfamide, navelbine and epirubicine as salvage chemotherapy in refractory germ cell tumors. Proc Am Soc Clin Oncol 1991; 10: 174.
53. Droz JP, Pico JL, Biron P et al. No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor-risk non seminomatous germ cell tumors: Preliminary results of a randomized trial. Proc Am Soc Clin Oncol 1992; 11: 197.
54. Droz JP, Pico JL, Ghosn M et al. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non-seminomatous germ cell tumors. Bull Cancer 1992; 79: 497-507.
55. Ozols RF, Ihde DC, Linehan WM et al. A randomized trial of standard chemotherapy v. a high dose chemotherapy regimen in the treatment of poor prognosis metastatic non-seminomatous germ-cell tumors. J Clin Oncol 1988; 6: 1031-40.
56. Motzer RJ, Mazumbar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-35.
57. Motzer RJ, Mazumbar M, Lyn P et al. High-dose carboplatin, etoposide and cyclophosphamide in first line therapy for poor-risk germ cell tumors. Proc Am Soc Clin Oncol 1996; 15: 251.
58. Broun ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124-8.
59. Rosti G, Albertazzi L, Salvioni R et al. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: A phase II study. Ann Oncol 1992; 3: 809-12.
60. Nichols CR, Andersen J, Lazarus HM et al, High-dose carboplatin and etoposide with autologous bone marrow transplantalion in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992; 10: 558-63.
61. Pico JL, Ibrahim A, Castagna L et al. Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. Oncology 1993; 50: 47-52.
62. Elias A, Kantoff P, Ayash L et al. High-dose ifosfamide, carboplatin and etoposide (ICE) with autologous bone marrow support for germ cell carcinoma. Proc Am Soc Clin Oncol 1993; 12: 231.
63. Margolin K, Doroshow J, Ahn C et al. High-dose carboplatin, VP-16 and ifosfamide with autologous bone marrow support in relapsed germ cell tumors. Proc Am Soc Clin Oncol 1993; 12: 252.
64. Broun ER, Nichols JL, Turns M et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994; 73: 1716-20.
65. Broun ER, Gize G, Nichols CR et al. Tandem autotransplantation for initial relapse of germ cell cancer. Proc Am Soc Clin Oncol 1995; 14: 243